Pharma 5.0 Market Global Report 2026

The pharma 5.0 market size has grown exponentially in recent years. It will grow from $78.54 billion in 2025 to $109.08 billion in 2026 at a compound annual growth rate (CAGR) of 38.9%. The growth in the historic period can be attributed to reliance on conventional pharmaceutical research and development processes, limited adoption of digital tools, growing demand for personalized therapies, increasing regulatory emphasis on patient outcomes, and continued investment in traditional manufacturing technologies.

The pharma 5.0 market size is expected to see exponential growth in the next few years. It will grow to $376.13 billion in 2030 at a compound annual growth rate (CAGR) of 36.3%. The growth in the forecast period can be attributed to increasing deployment of artificial intelligence-driven drug discovery platforms, expansion of cloud-based healthcare solutions, growing integration of robotic process automation and digital twins in pharmaceutical manufacturing, rising adoption of genomic sequencing and pharmacogenomics, and increasing collaboration between pharmaceutical companies and digital health startups. Major trends in the forecast period include greater integration of patient-centric digital health solutions, expansion of precision medicine and personalized treatment plans, increasing adoption of smart manufacturing and automation in pharmaceutical operations, growth of remote monitoring and virtual healthcare platforms, and rising use of predictive analytics in drug development and clinical trials.

The rising obesity prevalence is expected to propel the growth of the oral obesity therapies market going forward. Obesity refers to a medical condition characterized by an excessive accumulation of body fat that increases the risk of health problems such as heart disease, diabetes, and hypertension. Obesity is increasing primarily due to greater consumption of calorie-dense processed foods, which can result in excess energy intake and gradual weight gain when not balanced with sufficient physical activity. Oral obesity therapies help manage obesity by regulating hunger-related hormones and reducing calorie absorption, which supports sustained weight management and improved health outcomes. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, in 2023-2024, the prevalence of overweight, including obesity, among adults was higher in men at 69.7% than in women at 59.2%, whereas obesity alone was slightly more prevalent among women at 26.9% compared with 26.2% among men. Therefore, the rising obesity prevalence is driving the growth of the oral obesity therapies market.

Key companies operating in the pharma 5.0 market are focusing on developing advanced solutions, such as generative artificial intelligence (AI) cloud services, to accelerate drug discovery, optimize clinical trials, enhance personalized treatment plans, and improve overall operational efficiency. Generative artificial intelligence (AI) cloud services refer to cloud-based platforms that use AI models to create new content, insights, or solutions by learning patterns from existing data. For example, in March 2023, NVIDIA Corporation, a US-based technology company, launched BioNeMo Cloud, a revolutionary generative artificial intelligence (AI) platform designed to transform life sciences research and development. The new service was developed in collaboration with leading biotech and pharmaceutical companies, including Amgen and AstraZeneca, to deliver cutting-edge AI models for accelerated drug discovery. BioNeMo Cloud provides researchers with large language models (LLMs) tailored for biomolecular data, enabling rapid prediction of protein structures, molecular interactions, and novel drug candidates.

In May 2025, AstraZeneca plc, a UK-based pharmaceutical company, acquired EsoBiotec BV for an undisclosed amount. Through this acquisition, AstraZeneca aims to accelerate the advancement of EsoBiotec’s innovative in vivo cell therapy platform, transform the accessibility and delivery of cell therapies by reducing treatment durations from weeks to minutes, and extend affordable and scalable cancer and immune-mediated disease treatments to a larger global patient population. EsoBiotec BV is a Belgium-based biotechnology company specializing in AI-enabled in vivo cell therapies.

Major companies operating in the pharma 5.0 market are Pfizer Incorporated, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca Plc, Novartis AG, GSK Plc, Eli Lilly and Company, Ericsson AB, Merck KGaA, Moderna Inc., BioNTech SE, Teva Pharmaceuticals Industries Ltd., Rockwell Automation Inc., Sun Pharmaceutical Industries Ltd., 3D Systems Corporation, XtalPi Inc., Insilico Medicine Inc.

North America was the largest region in the pharma 5.0 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharma 5.0 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharma 5.0 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.